Press Releases Telo Genomics Corp. Toronto S.E.

Equities

TELO

CA87975M1095

End-of-day quote Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^PTS	-.--%		-.--%	-.--%

Jun. 21	Telo Genomics Corp. announced that it has received CAD 0.65 million in funding	CI
Jun. 18	Telo Genomics' Myeloma Test Accepted as Lab Developed Test by College of American Pathologists	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP	Jun. 18	NE
Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024	Jun. 12	NE
Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology	May. 30	NE
Telo Genomics and Emery Pharma Announce Collaboration	May. 15	NE
Telo Genomics Receives Accreditation from College of American Pathologists	Apr. 10	NE
Telo Genomics' Flagship MRD Clinical Trial Expands into Multi-Center Trial	Apr. 02	NE
Telo Genomics Initiates MRD Clinical Trial for Multiple Myeloma Patients	Feb. 13	NE
Telo Genomics Engages US Diagnostics Experts to Power Product Adoption in the US	Jan. 30	NE
Telo Genomics Gears up for American Society of Hematology Conference	Dec. 06	NE
Telo Genomics Launches Physician Experience Program in the United States	Nov. 16	NE
Telo Genomics Advances to the Final Stage of Accreditation from The College of American Pathologists	Nov. 07	NE
American Society of Hematology (ASH) Accepts Validation Data from Telo Genomics for Presentation at Upcoming Annual Meeting	Nov. 01	NE
Telo Genomics : Consolidated Financial Statements	23-10-29	PU
Telo Genomics Completes International Standards Organization ("ISO") 15189 Final Accreditation	23-10-26	NE
Telo Genomics Announces Clinical Launch of Non-Invasive Cancer Diagnostic, TeloViewSMM - An Important Commercial Milestone Achieved	23-10-17	NE
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting	23-10-12	NE
Telo Genomics Completes Oversubscribed Private Placement	23-06-15	AQ
Telo Genomics Achieves a Major Milestone - Results of Smoldering Myeloma Study Accepted for Presentation at ASCO Annual Meeting	23-04-14	AQ
Telo Genomics : Q1 - 2023	22-11-16	PU
Telo Genomics Engages Key Opinion Leader to Form and Chair Myeloma Advisory Board	22-10-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Telo Genomics Corp. Toronto S.E.

Equities

TELO

CA87975M1095

Press Releases

Filters